| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_cf32b60391b469c41e86c353437f5751 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-545
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-94
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-92
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-76
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-21
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-34
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-32 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-244
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-3955
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-02 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P19-02 |
| filingDate |
2016-10-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2020-07-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c4c9dafb51279265d94d691299a5ef16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ea622008cd7b1cd7972f979106ef9d12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_51ff9f79a75b8d29a385fe29dfd2fbb3 |
| publicationDate |
2020-07-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
RU-2728710-C2 |
| titleOfInvention |
Methods of treating non-radiographic axial spondylarthritis by using interleukin-17 (il-17) antagonists |
| abstract |
FIELD: medicine. n SUBSTANCE: group of inventions can be used for treating patients with non-radiation-axial spondylarthritis. That is ensured by administering an anti-IL-17 antibody such as secukinumab, or an antigen-binding fragment thereof. IL-17 antibody binds the epitope of IL-17 homodimer having two chains of mature IL-17 protein. Antibody to IL-17 or an antigen binding fragment has K D 100–200 pM and in vivo half-life of approximately 23–35 days. Also disclosed is a method of treating a patient having axial spondylarthritis. n EFFECT: group of inventions enables inhibiting the progression of structural injuries in the patients with non-radiographic axial spondylarthritis. n 20 cl, 3 dwg, 5 ex |
| priorityDate |
2015-10-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |